PT  - JOURNAL ARTICLE
AU  - Sinnott-Armstrong, Nasa
AU  - Klein, Daniel L.
AU  - Hickey, Brendan
TI  - Evaluation of Group Testing for SARS-CoV-2 RNA
AID  - 10.1101/2020.03.27.20043968
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.27.20043968
4099  - http://medrxiv.org/content/early/2020/03/30/2020.03.27.20043968.short
4100  - http://medrxiv.org/content/early/2020/03/30/2020.03.27.20043968.full
AB  - During the current COVID-19 pandemic, testing kit and RNA extraction kit availability has become a major limiting factor in the ability to determine patient disease status and accurately quantify prevalence. Current testing strategies rely on individual tests of cases matching restrictive diagnostic criteria to detect SARS-CoV-2 RNA, limiting testing of asymptomatic and mild cases. Testing these individuals is one effective way to understand and reduce the spread of COVID-19.Here, we develop a pooled testing strategy to identify these low-risk individuals. Drawing on the well-studied group testing literature, modeling suggests practical changes to testing protocols which can reduce test costs and stretch a limited test kit supply. When most tests are negative, pooling reduces the total number of tests up to four-fold at 2% prevalence and eight-fold at 0.5% prevalence. At current SARS-CoV-2 prevalence, randomized group testing optimized per country could double the number of tested individuals from 1.85M to 3.7M using only 671k more tests.This strategy is well-suited to supplement testing for asymptomatic and mild cases who would otherwise go untested, and enable them to adopt behavioral changes to slow the spread of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN.S.-A. is funded by a Stanford Graduate Fellowship.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a work of secondary analysis and all data are available from other studies or websites. An interactive simulation framework derived from the work presented in this study is available at https://technopolymath.shinyapps.io/pooled_covid_testing/. https://technopolymath.shinyapps.io/pooled_covid_testing/ https://ourworldindata.org/covid-testing